EUVIMEDEUVIMED entdecken
Crossref

Age at treatment initiation predicts response in children with chronic hepatitis B

Xiaoli Wu, Zhenzhen Yao, Xin Lai, Yingping Gu, Songxu Peng iD

Alimentary Pharmacology & Therapeutics · 2023

DOI: 10.1111/apt.17667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2023. Verfasst von Xiaoli Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Reproductive Medicine, Maternal and Child Health Hospital of Hunan Province, Changsha, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accumulating evidence suggests that age has a significant impact on disease progression and outcome of hepatitis B virus (HBV) infection. However, its effect on treatment response has not yet been fully elucidated.

Aim

To investigate the associations of age at treatment initiation with clinical treatment outcomes in children with chronic hepatitis B (CHB).

Methods

This study included 306 treatment‐naïve children with CHB. Participants were divided into three groups based on the age at which they started antiviral treatment: 1–3 years, 4–6 years and 7–17 years. The primary outcome of this study was HBsAg loss; secondary outcomes included HBeAg clearance and DNA undetectability.

Results

Of the 306 subjects, 200 (65.4%) were male. Median (IQR) duration of follow‐up was 26 (17, 42) months. There were 139 (45.4%), 79 (25.8%) and 88 (28.6%) of participants in the 1–3 years, 4–6 years and 7–17 years groups, respectively. After adjusting for other covariates, age at treatment initiation was negatively associated with the occurrence of HBsAg loss (1–3 years: HR = 5.07, 95% CI = 2.91–8.82; 4–6 years: HR = 2.42, 95% CI = 1.31–4.46) and HBeAg clearance (1–3 years: HR = 1.73, 95% CI = 1.18–2.53). In addition, we observed linear dose–responses relationships between age at treatment initiation and the probability of HBsAg loss and HBeAg clearance.

Conclusions

In children with CHB receiving antiviral treatment, HBsAg loss and HBeAg clearance were frequently observed. Age at treatment initiation can predict treatment response, including HBsAg loss and HBeAg clearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHumansMaleChildInfantChild, PreschoolFemaleHepatitis B Surface AntigensAntiviral AgentsHepatitis B e AntigensHepatitis B virusTreatment OutcomeDNA, Viral

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsHepatitis B e AntigensDNA, Viral

Autor:innen und Institutionen

  • Center for Reproductive Medicine, Maternal and Child Health Hospital of Hunan Province, Changsha, China.
  • Department of Maternal and Child Health, Xiangya School of Public Health, Central South University, Changsha, China.
  • NHC Key Laboratory of Birth Defect for Research and Prevention (Hunan Provincial Maternal and Child Health Care Hospital), Changsha, Hunan, China.

ORCID-Profile: Songxu Peng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, X., Yao, Z., Lai, X., Gu, Y., & Peng, S. (2023). Age at treatment initiation predicts response in children with chronic hepatitis B. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17667

Vancouver

Wu X, Yao Z, Lai X, Gu Y, Peng S. Age at treatment initiation predicts response in children with chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17667

BibTeX
@article{Wu2023,
  author = {Wu, Xiaoli and Yao, Zhenzhen and Lai, Xin and Gu, Yingping and Peng, Songxu},
  title = {Age at treatment initiation predicts response in children with chronic hepatitis B},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1111/apt.17667}
}
Kostenlos starten →